Chugai Pharmaceutical Co. (CHGCY)
(Delayed Data from OTC)
$23.71 USD
-0.12 (-0.50%)
Updated Nov 1, 2024 03:58 PM ET
4-Sell of 5 4
C Value A Growth A Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CHGCY 23.71 -0.12(-0.50%)
Will CHGCY be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for CHGCY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CHGCY
Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year?
Corcept Therapeutics Incorporated (CORT) Hits Fresh High: Is There Still Room to Run?
CHGCY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) Upgraded to Buy: Here's Why
Are Medical Stocks Lagging Brookdale Senior Living (BKD) This Year?
Other News for CHGCY
Chugai Pharmaceutical Co., Ltd. 2024 Q3 - Results - Earnings Call Presentation
Chugai Pharmaceutical Co., Ltd. (CHGCF) Q3 2024 Earnings Call Transcript
Roche advances AI-driven cancer diagnostics by expanding its digital pathology open environment
Harding Loevner International Developed Markets Equity Q2 2024 Report
Harding Loevner International Equity ADR Q2 2024 Report